Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial

Abstract Background Availability of potent anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKI) has pushed the median survival of ALK+ non-smallcell lung cancer (NSCLC) patients to over five years. In particular, second-generation ALK TKI have demonstrated superiority compared to the fi...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Petros Christopoulos, Farastuk Bozorgmehr, Lena Brückner, Inn Chung, Johannes Krisam, Marc A. Schneider, Albrecht Stenzinger, Regina Eickhoff, Daniel W. Mueller, Michael Thomas
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	BMC 2021-06-01
Schriftenreihe:	BMC Cancer
Schlagworte:	Non-small cell lung cancer Anaplastic lymphoma kinase ALK+ NSCLC Tyrosine kinase inhibitors (TKI) Brigatinib Resistance mutations
Online-Zugang:	https://doi.org/10.1186/s12885-021-08460-w
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!